 Home > Biochemistry News > Biotechnology News > Bleeding rate reduced by 84%, hemophilia A gene therapy phase 3 clinical results listed on NEJM

Bleeding rate reduced by 84%, hemophilia A gene therapy phase 3 clinical results listed on NEJM

 Last Update: 2022-04-28
 Source: Internet
 Author: User

Tags

environmental communication journal

water research journal

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On March 18, BioMarin Pharmaceutical announced that the results of the Phase 3 clinical trial of the gene therapy valoctocogene roxaparvovec for the treatment of severe hemophilia A were published in the prestigious medical journal The New England Journal of Medicine

Hemophilia A is a rare inherited bleeding disorder caused by a deficiency of factor VIII

Valoctocogene roxaparvovec is a gene therapy that uses an AAV5 viral vector to deliver a transgene expressing Factor VIII

Published study results showed that following a single infusion of valoctocogene roxaparvovec, subjects experienced significantly lower annual bleeding rate (ABR), less frequent factor VIII use, and increased factor VIII activity compared to data from the year prior to enrollment

References:

[1] BioMarin Announces Publication in New England Journal of Medicine of One-Year Results from Phase 3 Pivotal Trial with Valoctocogene Roxaparvovec Gene Therapy in Adults with Severe Hemophilia A.

(Original abridged)

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Frontier bleeding rate reduced by 84%, hemophilia A gene therapy Phase 3 clinical results listed on NEJM

04-30

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.

Bleeding rate reduced by 84%, hemophilia A gene therapy phase 3 clinical results listed on NEJM

Related Articles

Frontier bleeding rate reduced by 84%, hemophilia A gene therapy Phase 3 clinical results listed on NEJM